Abstract
Introduction . The respiratory syncytial virus is one of the leading causes of lower respiratory tract infections in premature children. An effective way to prevent respiratory syncytial viral infection is passive immunization with palivizumab. However, its capabilities and results in children born with very low and extremely low body weight have not been sufficiently studied. Objective. To evaluate the effectiveness of passive immunization in the prevention of respiratory syncytial viral infection in children born with very low and extremely low body weight. Children characteristics and research methods . The authors studied the frequency and severity of respiratory diseases in 450 patients born with very low and extremely low body weight. 385 children (Group 1) received palivizumab, 65 children (Group 2) did not receive palivizumab. In both groups there was the same frequency of bronchopulmonary dysplasia (68,8 and 69,0%, respectively) Results. There were no complications after palivizumab administration; 32 (8,3%) children had mild catarrhal phenomena without hyperthermia, 3 (0,8%) children had local skin reactions. During observation period up to 9±1 months the authors noted a lower incidence of respiratory diseases (p=0,0002) in Group 1 as compared with Group 2, including moderate forms of ARVI (p=0,0078); none of the children got sick due to the respiratory syncytial virus. In Group 2 the virus was detected in 3 out of 7 children with a severe respiratory infection. The immunized children were less likely to be hospitalized (p=0,0175), including in the intensive care unit and intensive care unit (p=0,0034) and to be prescribed antibiotic therapy (p=0,0045). There was the higher risk of recurrent diseases in both groups. The patients with bronchopulmonary dysplasia with comorbid conditions were at higher risk of recurrent diseases in both groups. Conclusion. Children born with very low and extremely low body weight shall be given passive immunoprophylaxis against RSV infection.
Highlights
The respiratory syncytial virus is one of the leading causes of lower respiratory tract infections in premature children
The authors studied the frequency and severity of respiratory diseases in 450 patients born with very low and extremely low body weight. 385 children (Group 1) received palivizumab, 65 children (Group 2) did not receive palivizumab. In both groups there was the same frequency of bronchopulmonary dysplasia (68,8 and 69,0%, respectively) Results
There were no complications after palivizumab administration; 32 (8,3%) children had mild catarrhal phenomena without hyperthermia, 3 (0,8%) children had local skin reactions
Summary
Опыт пассивной иммунопрофилактики против респираторно-синцитиальной вирусной инфекции у детей, рожденных с очень низкой и экстремально низкой массой тела. Однако ее возможности и результаты у детей, родившихся с очень низкой и экстремально низкой массой тела, изучены недостаточно. Оценка эффективности пассивной иммунизации в профилактике респираторно-синцитиальной вирусной инфекции у детей, родившихся с очень низкой и экстремально низкой массой тела. Изучены частота и тяжесть заболеваний органов дыхания у 450 пациентов, родившихся с очень низкой и экстремально низкой массой тела; 385 детей (1-я группа) получали препарат паливизумаб, 65 (2-я группа) – не получали. Детям с экстремально низкой и очень низкой массой тела при рождении необходимо и возможно проведение пассивной иммунопрофилактики против респираторно-синцитиальной вирусной инфекции.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
